Search Legislation

Advanced Search

Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC)

Help about what version

What Version

More Resources

Revised version PDFs

Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Changes to legislation:

There are outstanding changes not yet made to Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC). Those changes will be listed when you open the content using the Table of Contents below. Any changes that have already been made to the legislation appear in the content and are referenced with annotations. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the affected provisions when you open the content using the Table of Contents below.

View outstanding changes

Changes and effects yet to be applied to :

  • Annex Point 2 Text addition by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.4.2 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 2 Text replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Table 3 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.1.11 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.1.1 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Table 4 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.1.3 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Table 1 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.1.9 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Decision revoked by S.I. 2002/618, reg. 4H(1) (as inserted) by S.I. 2019/791 reg. 3(7)
  • Annex point 3.1.4 words substituted by S.I. 2021/873 Sch. 2 para. 3(a)(i)
  • Annex point 3.1.4 words substituted by S.I. 2021/873 Sch. 2 para. 3(a)(ii)
  • Annex point 3.1.8 words substituted by S.I. 2021/873 Sch. 2 para. 3(b)(i)
  • Annex point 3.1.8 words substituted by S.I. 2021/873 Sch. 2 para. 3(b)(ii)
  • Annex point 3.4.1 words substituted by S.I. 2021/873 Sch. 2 para. 3(c)(i)
  • Annex point 3.4.1 words substituted by S.I. 2021/873 Sch. 2 para. 3(c)(ii)
  • Annex words substituted by S.I. 2021/873 Sch. 2 para. 3(d)
  • Art. 1 words inserted by S.I. 2021/873 Sch. 2 para. 1
  • Art. 2 omitted by S.I. 2021/873 Sch. 2 para. 2

  1. Introductory Text

  2. Article 1.The technical specifications set out in the Annex to this...

  3. Article 2.This Decision is addressed to the Member States.

    1. ANNEX

      COMMON TECHNICAL SPECIFICATIONS (CTS) FOR IN VITRO DIAGNOSTIC MEDICAL DEVICES

      1. 1. SCOPE

      2. 2. DEFINITIONS AND TERMS

        1. (Diagnostic) sensitivity

        2. True positive

        3. False negative

        4. (Diagnostic) specificity

        5. False positive

        6. True negative

        7. Analytical sensitivity

        8. Analytical specificity

        9. Nucleic acid amplification techniques (NAT)

        10. Rapid test

        11. Robustness

        12. Whole system failure rate

        13. Confirmation assay

        14. Virus typing assay

        15. Sero-conversion HIV samples

        16. Early sero-conversion HIV samples

      3. 3. COMMON TECHNICAL SPECIFICATIONS (CTS) FOR PRODUCTS REFERRED TO IN ANNEX...

        1. 3.1. CTS for performance evaluation of reagents and reagent products for...

          1. General principles

            1. 3.1.1. Devices which detect virus infections shall meet the requirements for...

            2. 3.1.2. Devices intended by the manufacturer for testing body fluids other...

            3. 3.1.3. Devices intended by the manufacturer for self-test, i.e. home use,...

            4. 3.1.4. All performance evaluations shall be carried out in direct comparison...

            5. 3.1.5. If discrepant test results are identified as part of an...

            6. 3.1.6. Performance evaluations shall be performed on a population equivalent to...

            7. 3.1.7. Positive specimens used in the performance evaluation shall be selected...

            8. 3.1.8. Sensitivity with true positives and sero-conversion samples shall be evaluated...

            9. 3.1.9. Performance evaluation of screening assays shall include 25 positive (if...

            10. 3.1.10. Negative specimens used in a performance evaluation shall be defined...

            11. 3.1.11. For performance evaluations for screening assays (Table 1) blood donor...

            12. 3.1.12. Devices shall have a specificity of at least 99,5 % on...

            13. 3.1.13. Devices shall be evaluated to establish the effect of potential...

            14. 3.1.14. For devices intended by the manufacturer to be used with...

            15. 3.1.15. For devices intended for use with plasma the performance evaluation...

            16. 3.1.16. As part of the required risk analysis the whole system...

            17. 3.1.17. If a new in vitro diagnostic medical device belonging to...

        2. 3.2. Additional requirements for HIV and HCV antigen and antibody combined...

          1. 3.2.1. HIV antigen and antibody combined tests intended for the detection...

          2. 3.2.2. Hepatitis C virus (HCV) antigen and antibody combined tests intended...

        3. 3.3. Additional requirements for nucleic acid amplification techniques (NAT)

          1. 3.3.1. For target sequence amplification assays, a functionality control for each...

          2. 3.3.2. The analytical sensitivity or detection limit for NAT assays shall...

          3. 3.3.2a. Qualitative HIV NAT assays intended to be used to detect...

          4. 3.3.2b. Qualitative HIV NAT assays, other than virus typing assays, shall...

          5. 3.3.3. Genotype detection shall be demonstrated by appropriate primer or probe...

          6. 3.3.4. Results of quantitative NAT assays shall be traceable to international...

          7. 3.3.5. NAT assays may be used to detect virus in antibody...

          8. 3.3.6. For investigation of potential carry-over, at least five runs with...

          9. 3.3.7. The whole system failure rate leading to false-negative results shall...

        4. 3.4. CTS for the manufacturer’s release testing of reagents and reagent...

          1. 3.4.1. The manufacturer’s release testing criteria shall ensure that every batch...

          2. 3.4.2. The manufacturer’s batch release testing for screening assays shall include...

        5. 3.5. CTS for performance evaluation of reagents and reagent products for...

          1. 3.5.1. All performance evaluations shall be carried out in direct comparison...

          2. 3.5.2. If discrepant test results are identified as part of an...

          3. 3.5.3. Performance evaluations shall be performed on a population equivalent to...

          4. 3.5.4. Positive specimens used in the performance evaluation shall be selected...

          5. 3.5.5. Devices shall be evaluated to establish the effect of potential...

          6. 3.5.6. For devices intended for use with plasma the performance evaluation...

        6. 3.6. CTS for the manufacturer’s release testing of reagents and reagent...

          1. 3.6.1. The manufacturer’s release testing criteria shall ensure that every batch...

          2. 3.6.2. Requirements for manufacturers batch release testing are outlined in Table...

        7. 3.7. CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening...

        8. Acceptance criteria:

        9. Qualifications:

        10. Table 10 Batch release criteria for reagents and reagent products to determine...Specificity testing requirements on each reagent 1. Test reagents Only...

          1. 1. Test reagents

            1. Acceptance criteria:

          2. 2. Control materials (red cells)

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources